In an Aβ-induced ICR mouse model of AD, the administration of AS-IV reduced neuroinflammation and neuronal damage by reversing the Aβ-induced increase in TNF-α, IL-1β, and IL-6 levels in a dose-dependent manner [162]. This evidence concerns the gene IL6 and Alzheimer disease.